Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).

PloS one - 1 Jan 2015

Zorn Julie A, Wang Qi, Fujimura Eric, Barros Tiago, Kuriyan John

Abstract excerpt

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib. FLT3 with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Baculoviridae
Share to Benzothiazoles
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Phenylurea Compounds

Share to Sf9 Cells

Share to Spodoptera

Source

Open in PubMed Open full text

Identifiers

PMID: 25837374
DOI: 10.1371/journal.pone.0121177
PMCID: PMC4383440

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).PMID 25837374Read ↗

The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.Semantic proximity Read ↗

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read ↗

Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells.Semantic proximity Read ↗

Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.Semantic proximity Read ↗

Quizartinib for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib.Semantic proximity Read ↗

FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.Semantic proximity Read ↗

Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.Semantic proximity Read ↗

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AMLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.